Development and application of an enzyme immunoassay for tenascin

The matrix protein tenascin-C (TN-C) is present in the blood of healthy individuals at concentrations around 1 mg/l. Elevated serum levels have been reported in cancer patients. In this study we have measured the concentration of circulating TN-C in 40 patients with melanoma, soft-tissue sarcoma (STS) or squamous-cell carcinoma (SCC) of the limbs, and have found a minor increase in the mean concentration compared with healthy subjects. Only 10 patients had TN-C levels above the normal range. No correlation was observed between TN-C levels and tumor burden. Nineteen patients were treated by isolation limb perfusion (ILP) with TNF, IFN gamma, melphalan (11 melanoma, 2 SCC and I STS), melphalan alone (3 melanoma) or hyperthermia at 41.5 degrees C (2 melanoma). ILP with TNF, IFN gamma and melphalan induced a rapid increase in plasma TN-C levels, peaking in most patients between 24 or 48 hr after ILP. Two patients treated with hyperthermia only had a slow increase in TN-C concentration peaking at day 4, while the patients treated with melphalan alone had no significant change. In some cases elevated TN-C levels persisted for over 8 weeks after ILP. The early rise in TN-C concentration correlates with the increase in circulating C-reactive protein. Our findings suggest that circulating TN-C behaves, at least in part, as an acute-phase protein and that it may play a role in the inflammatory response.

show abstract

“…Kimura et al (1993) and Washizu et (11. (1993) reported TN (1994) reported TN-C levels in sera obtained from healthy individuals (0.86 ?…”

Section: Discussionmentioning

confidence: 94%

Rapid increase in plasma tenascin‐C concentration after isolated limb perfusion with high‐dose tumor necrosis factor (TNF), interferon gamma (IFNγ) and melphalan for regionally advanced tumors

Schenk

Líénard

Gérain

et al. 1995

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Our own and other groups have reported that abnormal serum tenascin-C concentrations associated with malignant disease [17,18,19,20,21,22]. Additionally, elevated tenascin-C serum levels have been found to be correlated with C-reactive protein (CRP) levels in serum [23].…”

Section: Introductionmentioning

confidence: 94%

Serum tenascin-C is an indicator of inflammatory bowel disease activity

Riedl

Tandara

Reinshagen

et al. 2001

Int J Colorectal Dis

View full text Add to dashboard Cite

Tenascin-C is a multifunctional matrix protein that is induced in inflammation and neoplasia. In the colonic mucosa of ulcerative colitis patients tenascin-C indicates tissue repair, and mucosal concentrations are correlated with local disease activity. We prospectively examined the relationship between serum concentrations of tenascin-C parameters of disease activity in surgically treated patients with ulcerative colitis and patients with inflammatory bowel disease (IBD). Perioperative serum concentrations were quantified by ELISA in 58 patients admitted for restorative proctocolectomy; controls were 37 patients with familial adenomatous polyposis receiving the same treatment. We also measured tenascin-C serum levels in 47 patients with ulcerative colitis and Crohn's disease who were receiving nonsurgical treatment. Preoperative serum tenascin-C levels were significantly higher in ulcerative colitis patients than in controls (17.2 +/- 14.6 microg/ml vs. 3.2 +/- 1.7 microg/ml) and were significantly correlated with clinical and histological parameters of disease activity; levels decreased significantly after restorative proctocolectomy. Serum tenascin-C levels were also correlated with the course of disease activity in conservatively treated IBD patients. Tenascin-C is thus not disease-specific. However, it does indicate the activity of IBD and may reflect the degree of tissue remodeling. The tenascin-C levels therefore offers a novel serum parameter for assessing disease activity and monitoring therapy in patients with IBD.

show abstract

“…Serological ECM markers have been measured in breast cancer, colon cancer, and malignant lymphoma. In melanoma, only tenascin‐C has been investigated to date 4,5 …”

Section: Introductionmentioning

confidence: 99%

“…In melanoma, only tenascin-C has been investigated to date. 4,5 In the present study, we measured hyaluronan, laminin-1, tenascin-C, and type VI collagen in the serum of malignant melanoma patients with an automated sandwich enyme-linked immunosorbent assay (ELISA). The patients either had primary melanomas (stage I ⁄ II) or distant melanoma metastasis (stage IV).…”

Section: Introductionmentioning

confidence: 99%

Laminin, hyaluronan, tenascin-C and type VI collagen levels in sera from patients with malignant melanoma

Burchardt

Hein

Bosserhoff

2003

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

In this study, hyaluronan, laminin-1, tenascin-C and type VI collagen were measured in the sera of patients with stage I/II and stage IV melanoma. A significant increase in the serum levels of all four extracellular matrix proteins was found in patients with stage IV melanoma compared to healthy donors. Type VI collagen and hyaluronan serum levels were also significantly increased in stage I/II melanoma. Increased expression of the four matrix proteins was also demonstrated in melanoma cell lines using reverse transcriptase- polmerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). We suggest that tenascin-C, hyaluronan, laminin-1 and type VI collagen are involved in melanoma development and extracellular matrix remodelling during melanoma progression. This finding will be of interest in the development of serum markers for progression of malignant melanoma.

show abstract

Development and application of an enzyme immunoassay for tenascin

Cited by 18 publications

References 12 publications

Rapid increase in plasma tenascin‐C concentration after isolated limb perfusion with high‐dose tumor necrosis factor (TNF), interferon gamma (IFNγ) and melphalan for regionally advanced tumors

Rapid increase in plasma tenascin‐C concentration after isolated limb perfusion with high‐dose tumor necrosis factor (TNF), interferon gamma (IFNγ) and melphalan for regionally advanced tumors

Serum tenascin-C is an indicator of inflammatory bowel disease activity

Laminin, hyaluronan, tenascin-C and type VI collagen levels in sera from patients with malignant melanoma

Contact Info

Product

Resources

About